Bone densitometry firm CompuMed has announced that it has received a letter of intent from Johns Hopkins University School of Medicine of Baltimore and Johns Hopkins University Applied Physics Laboratory of Laurel, MD, to collaborate on the development
Bone densitometry firm CompuMed has announced that it has received a letter of intent from Johns Hopkins University School of Medicine of Baltimore and Johns Hopkins University Applied Physics Laboratory of Laurel, MD, to collaborate on the development of a 3-D musculoskeletal imaging system developed by the two Johns Hopkins institutions.
Through research funded by NASA, the two institutions are refining a 3-D musculoskeletal imaging system that may yield precise measurement of bone and muscle structure and strength, according to Manhattan Beach, CA-based CompuMed. The system uses a high-resolution x-ray scanning technique that images bones with several projections in different directions, allowing for more accurate dimension measurements and the generation of 3-D engineering models of the subjects bones, according to the company.
The system employs an amorphous silicon flat-panel digital x-ray detector provided by Palo Alto, CA, companies Varian Medical Systems and dpiX. CompuMed employs a similar version of the detector in its Digital OsteoView 2000 system. Under the terms of the agreement, JHU and CompuMed will explore commercialization of the scanner for use in assessment of bone strength changes in osteoporosis.
Engineering resources at APL will also be deployed to complete the manufacturing design and augment the clinical capability of Digital OsteoView 2000. As part of the agreement, the utility of JHU-developed technologies will be evaluated for inclusion in current or future CompuMed products, according to the firm.
Study: AI Boosts Ultrasound AUC for Predicting Thyroid Malignancy Risk by 34 Percent Over TI-RADS
February 17th 2025In a study involving assessment of over 1,000 thyroid nodules, researchers found the machine learning model led to substantial increases in sensitivity and specificity for estimating the risk of thyroid malignancy over traditional TI-RADS and guidelines from the American Thyroid Association.
Can CT-Based AI Provide Automated Detection of Colorectal Cancer?
February 14th 2025For the assessment of contrast-enhanced abdominopelvic CT exams, an artificial intelligence model demonstrated equivalent or better sensitivity than radiologist readers, and greater than 90 percent specificity for the diagnosis of colorectal cancer.
Emerging PET/CT Agent Shows Promise in Detecting PCa Recurrence in Patients with Low PSA Levels
February 13th 202518F-DCFPyL facilitated detection of recurrent prostate cancer in 51 percent of patients with PSA levels ranging between 0.2 to 0.5 ng/ml, according to new research presented at the American Society of Clinical Oncology Genitourinary Cancers (ASCO-GU) Symposium.